Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Douglas F, Beach"'
Autor:
Ian W. Flinn, John G. Gribben, Ryan Jacobs, Monika Długosz-Danecka, John M. Burke, Tomasz Wróbel, Michael S. Weiss, Danielle M. Brander, Jeff P. Sharman, Peter Sportelli, Douglas F. Beach, Krzysztof Giannopoulos, Hari P. Miskin, Suman Kambhampati, Kathryn S. Kolibaba, Sebastian Grosicki, Nilanjan Ghosh, John M. Pagel, Jerome H. Goldschmidt, Tanya Siddiqi, Alexey V. Danilov, Javier Pinilla Ibarz, Jennifer L. Cultrera, Syed F. Zafar, Wojciech Jurczak, Owen A. O'Connor, Scott F. Huntington
Publikováno v:
Blood. 136:37-39
Background: Umbralisib is an oral, once-daily, novel, dual inhibitor of phosphatidylinositol-3-kinase-delta (PI3Kδ) and casein kinase-1ε (CK1ε) that exhibits improved selectivity for the delta isoform of PI3K. Ublituximab is a novel anti-CD20 mono
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b709026b6839fc03b0b3e79475cb12b
https://doi.org/10.1182/blood-2020-134783
https://doi.org/10.1182/blood-2020-134783
Autor:
Erica B. Bhavsar, Anthony R. Mato, Paul M. Barr, John M. Pagel, Ryan Jacobs, Chadi Nabhan, Jeffrey J. Pu, Joanna Rhodes, Nirav N. Shah, Clive S. Zent, Sasanka M. Handunnetti, Brian T. Hill, Alan P Skarbnik, Frederick Lansigan, Jakub Svoboda, John N. Allan, Chaitra S. Ujjani, Andre Goy, Hande H. Tuncer, Constantine S. Tam, Bruce D. Cheson, Stephen J. Schuster, Lindsey E. Roeker, Peter V. Pickens, Richard R. Furman, Danielle M. Brander, Alison R. Sehgal, Douglas F. Beach, Mazyar Shadman, Nicole Lamanna
Publikováno v:
Am J Hematol
Ibrutinib demonstrated superior response rates and survival for treatment-naïve chronic lymphocytic leukemia (CLL) patients in a pivotal study that excluded patients younger than 65 (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca9f0b2ab0c356e3f1536fcc104b3970
https://doi.org/10.1002/ajh.25261
https://doi.org/10.1002/ajh.25261
Autor:
Krzysztof Giannopoulos, Sebastian Grosicki, Jeff P. Sharman, Ryan Jacobs, Syed F. Zafar, Michael S. Weiss, Danielle M. Brander, Peter Sportelli, Douglas F. Beach, Scott F. Huntington, Hari P. Miskin, Owen A. O'Connor, Wojciech Jurczak, Nilanjan Ghosh, Javier Pinilla Ibarz, Ian W. Flinn, John M. Pagel, Jerome H. Goldschmidt, Monika Długosz-Danecka, Suman Kambhampati, Tanya Siddiqi, John M. Burke, Tomasz Wróbel, John G. Gribben, Mazyar Shadman, Kathryn S. Kolibaba, Alexey V. Danilov, Jennifer L. Cultrera
Publikováno v:
Blood. 138:3726-3726
Background: Umbralisib, a selective PI3Kδ and casein kinase-1epsilon (CK1ε) inhibitor, is pharmacologically distinct from other PI3K inhibitors and is administered orally once daily. Ublituximab is a novel anti-CD20 monoclonal antibody glycoenginee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5497f3c48810d5c73ddd5b246479d7a
https://doi.org/10.1182/blood-2021-147460
https://doi.org/10.1182/blood-2021-147460
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 27(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66d28d246ec067638aed431bd0f49efe
https://pubmed.ncbi.nlm.nih.gov/27573566
https://pubmed.ncbi.nlm.nih.gov/27573566
Autor:
Hana Aviv, Vimal Patel, Roland Schwarting, Neil A. Lachant, Douglas F. Beach, Barry L. Barnoski, Roger Strair
Publikováno v:
Cancer Genetics. 205:665-668
A nonrandom structural gain of 1q may be seen in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), and often it is due to an unbalanced translocation. Dup(1)(q21q32) as the sole abnormality has only rarely been reported. Reports have s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6419bba95a0f80ca5189a17f7b933224
https://doi.org/10.1016/j.cancergen.2012.09.004
https://doi.org/10.1016/j.cancergen.2012.09.004
Autor:
Douglas F, Beach, Robert A, Somer, Jean, Hoffman-Censits, Jianqing, Lin, Yu-Ning, Wong, Elizabeth, Plimack, Elizabeth, Plimeck, Gary, Hudes, David, Vaughn, Guy T, Bernstein, Gloria J, Morris
Publikováno v:
Seminars in Oncology. 39:1-8
a t f t p p t At times we encounter clinical problems for which there are no directly applicable evidence-based solutions, but we are compelled by circumstances to act. When doing so we rely on related evidence, general principles of best medical pra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7741c362c3e8b7336702845e17b4130d
https://doi.org/10.1053/j.seminoncol.2011.11.001
https://doi.org/10.1053/j.seminoncol.2011.11.001
Autor:
Roland Schwarting, Douglas F. Beach, Lisa M. Reid, Alexandre Hageboutros, Ghada Haddad, William Klump
Publikováno v:
Medical Oncology. 29:1405-1408
Neuroendocrine tumors comprise a large group of malignancies which share unique morphological features and are characterized by the presence of neuroendocrine markers such as synaptophysin, chromogranin-A, and CD56 (N-CAM), ranging from indolent tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7a3c27907f7ce265acd34d51550b7ff
https://doi.org/10.1007/s12032-011-9996-7
https://doi.org/10.1007/s12032-011-9996-7
Autor:
Robert A. Somer, Douglas F. Beach
Publikováno v:
Journal of Clinical Oncology. 29:e397-e401
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39d0c6242d04dfcab967fbdd037a9a07
https://doi.org/10.1200/jco.2010.33.3393
https://doi.org/10.1200/jco.2010.33.3393
Autor:
Ohad Oren, Douglas F. Beach
Publikováno v:
Blood. 128:3593-3593
Background Non-cancerous medical conditions have a profound impact on the health of patients with malignancies. In individuals with lung cancer, the likelihood of death due to other causes is higher than that of the general population. It is therefor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75987f6e6b1235283455b2a1b4b4f445
https://doi.org/10.1182/blood.v128.22.3593.3593
https://doi.org/10.1182/blood.v128.22.3593.3593
Autor:
Douglas F. Beach, Ohad Oren
Publikováno v:
Journal of Clinical Oncology. 34:e18057-e18057
e18057Background: African-American (AA) men represent a unique subset of patients in prostate cancer. First, they are disproportionately affected by this cancer, with prevalence rates of 214.5 (per...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd846fe638422280da43e2d0b008fac1
https://doi.org/10.1200/jco.2016.34.15_suppl.e18057
https://doi.org/10.1200/jco.2016.34.15_suppl.e18057